Track topics on Twitter Track topics that are important to you
The PODD teams bring to the West Coast a Drug Delivery Design & Partnering Meeting. This inaugural program focuses on meeting the design needs of drug delivery systems from the perspectives of pharma, physicians, patients, investors, as well as KOLs in personalized medicine and digital.
NEW YORK (PRWEB) March 16, 2018
The Conference Forum is pleased to bring the inaugural Drug Delivery Design & Partnering conference to the Mark Hopkins Intercontinental Hotel in San Francisco on May 21-22, 2018. Organized by the company's PODD team, this west coast event is dedicated to meeting the design needs of drug delivery systems from a variety of different industry perspectives.
"At this inaugural event, we are bringing together physicians, patients, KOLs and industry to understand and discuss how to improve the design and development of drug delivery systems to better meet the needs of patients," said conference producer Michelle McDermott.
Led by chair Dr Ann Daugherty, Genentech, the first day of the program opens with observations on key trends in drug delivery. Dr Daugherty will moderate the first physicians' POV panel on current and future drug delivery needs. Panelists include Dr Mark Blumenkranz of Stanford University, Dr Krishnan Chakravaty of the University of California, San Diego, Dr Bruce Kovacs of Afecta Pharmaceuticals/USC, and Dr Julia Ljubimova of Cedars-Sinai.
The patient perspective follows with a panel on what patients want from drug delivery technologies. The spotlight turns to pharma companies, who discuss their current needs, partnering philosophy and scouting interests with Dr Daugherty, Dr John Higgins, Merck, Dr Sudeshna Dutta Ray, Amgen and Dr James Cunningham, Allergan.
The program continues in the afternoon with the opportunity to assess a wide variety of drug delivery technologies in "quick fire" presentations in two tracks. Track One on Formulation Technologies is chaired by Dr Cunningham. Track Two on Device Technologies is chaired by Sheldon Moberg of Amgen.
Day two kicks off with Dr Michael Blum of UCSF School of Medicine, who delivers the personalized medicine KOL perspective for drug delivery. Cambridge Design Partnership's, Uri Barach will walk attendees through the design innovation process and Dr Jonathan Usuka, McKinsey will give the run down on the evolving digital R&D landscape and the impact on drug delivery.
The morning continues with a Novartis case study on connected smart devices given by Dr Gabriel Iobbi. Dr Sherri Biondi of MedImmune then discusses device design, in particular the current thinking on integrating human factors with digital technologies to increase patient adherence and satisfaction.
Next, Brent Ahrens of Canaan Partners, Andrew Farquharson of InCube Ventures and Dr Garrett Vygantas of OSF Healthcare Ventures join together to discuss investor perspectives on how analysts and investors look at drug delivery and what they want to see. Finally, Dr John Patton of Dance Biopharma talks about lessons learned from past designs and what we should be aware of for the future.
For more information, visit Drug Delivery Design & Partnering conference.
About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance patient-centered clinical research and drug delivery systems.
For the original version on PRWeb visit: http://www.prweb.com/releases/2018/03/prweb15327575.htmNEXT ARTICLE
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...